Rhythm Pharmaceuticals (RYTM) Change in Acquisitions & Divestments (2016 - 2026)

Rhythm Pharmaceuticals (RYTM) has 11 years of Change in Acquisitions & Divestments data on file, last reported at $99.3 million in Q1 2026.

• On a quarterly basis, Change in Acquisitions & Divestments rose 70.15% year-over-year to $99.3 million in Q1 2026; TTM through Mar 2026 was $293.4 million, a 17.86% increase from a year earlier, with the FY2025 full-year figure at $252.5 million, down 3.13% from the prior year.
• Change in Acquisitions & Divestments for Q1 2026 stood at $99.3 million, up from $51.6 million in the prior quarter.
• Over the last five years, Change in Acquisitions & Divestments for RYTM reached as high as $124.5 million in Q2 2023 and fell as low as $45.3 million in Q3 2024.
• Historically, Change in Acquisitions & Divestments has averaged $73.6 million across 5 years, with a median of $63.3 million in 2023.
• Across the five-year window, Change in Acquisitions & Divestments slumped 60.76% in 2022 and surged 144.12% in 2023, its largest moves.
• Year by year, Change in Acquisitions & Divestments stood at $59.6 million in 2022, then increased by 6.12% to $63.3 million in 2023, then jumped by 38.3% to $87.5 million in 2024, then tumbled by 41.0% to $51.6 million in 2025, then surged by 92.17% to $99.3 million in 2026.
• Per Business Quant data, the three most recent Change in Acquisitions & Divestments figures were $99.3 million in Q1 2026, $51.6 million in Q4 2025, and $61.5 million in Q3 2025.